Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1)
Acromegaly (PATHFNDR-2)
Carcinoid Syndrome
Congenital Adrenal Hyperplasia (CAH)
PTH Antagonist, Hyperparathyroidism
SST3 Agonist, Polycystic Kidney Disease
TSH Antagonist, Graves' Disease, TED
Oral GLP-1 nonpeptide, Diabetes, Obesity
Oral GIP nonpeptide, Diabetes, Obesity
SST5 Agonist, Hyperinsulinism
Radionetics, Targeted Radiotherapy | Multiple Solid-Tumor Oncology Company
Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1)
Acromegaly (PATHFNDR-2)
Carcinoid Syndrome
Congenital Adrenal Hyperplasia (CAH)
PTH Antagonist, Hyperparathyroidism
Undisclosed, Polycystic Kidney
TSH Antagonist, Graves' Disease, TED
Undisclosed (Multiple), Diabetes, Obesity
SST5 Agonist, Hyperinsulinism
Radionetics, Targeted Radiotherapy | Multiple Solid-Tumor Oncology Company

Paltusotine(oral SST2 agonist)


In development for the treatment of acromegaly, neuroendocrine tumors (NETs) and carcinoid syndrome, our lead product candidate establishes a new class of oral, selective, nonpeptide, somatostatin receptor type 2 (SST2) agonist.

CRN04894(oral ACTH antagonist)


This is the first oral, selective ACTH antagonist in development for the treatment of Cushing’s disease and other diseases of excess ACTH, such as congenital adrenal hyperplasia (CAH).